Mario Tiribelli

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2131005/publications.pdf

Version: 2024-02-01

256	4,829	117625	128289
papers	citations	34 h-index	60 g-index

260	260	260	5227
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Contribution of ABL Kinase Domain Mutations to Imatinib Resistance in Different Subsets of Philadelphia-Positive Patients: By the GIMEMA Working Party on Chronic Myeloid Leukemia. Clinical Cancer Research, 2006, 12, 7374-7379.	7.0	475
2	Nilotinib for the frontline treatment of Ph+ chronic myeloid leukemia. Blood, 2009, 114, 4933-4938.	1.4	203
3	The efficacy of imatinib mesylate in patients with FIP1L1-PDGFRÂ-positive hypereosinophilic syndrome. Results of a multicenter prospective study. Haematologica, 2007, 92, 1173-1179.	3.5	198
4	Functional integrity of the p53-mediated apoptotic pathway induced by the nongenotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood, 2006, 107, 4122-4129.	1.4	156
5	Life after ruxolitinib: Reasons for discontinuation, impact of disease phase, and outcomes in 218 patients with myelofibrosis. Cancer, 2020, 126, 1243-1252.	4.1	106
6	Investigating factors associated with adherence behaviour in patients with chronic myeloid leukemia: an observational patient-centered outcome study. British Journal of Cancer, 2012, 107, 904-909.	6.4	100
7	Frontline imatinib treatment of chronic myeloid leukemia: no impact of age on outcome, a survey by the GIMEMA CML Working Party. Blood, 2011, 117, 5591-5599.	1.4	97
8	The prognostic value of P-glycoprotein (ABCB) and breast cancer resistance protein (ABCG2) in adults with de novo acute myeloid leukemia with normal karyotype. Haematologica, 2006, 91, 825-8.	3.5	92
9	Residual Peripheral Blood CD26+ Leukemic Stem Cells in Chronic Myeloid Leukemia Patients During TKI Therapy and During Treatment-Free Remission. Frontiers in Oncology, 2018, 8, 194.	2.8	84
10	Anti-CD20 Therapy for Chronic Lymphocytic Leukemia-associated Autoimmune Diseases. Leukemia and Lymphoma, 2003, 44, 1951-1955.	1.3	83
11	Nutlin-3 up-regulates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feedback antiapoptotic mechanism. Blood, 2009, 113, 4300-4308.	1.4	83
12	Quantitative assessment of WT1 gene expression after allogeneic stem cell transplantation is a useful tool for monitoring minimal residual disease in acute myeloid leukemia. European Journal of Haematology, 2009, 82, 61-68.	2.2	78
13	Differences among young adults, adults and elderly chronic myeloid leukemia patients. Annals of Oncology, 2015, 26, 185-192.	1.2	72
14	The BCRâ€ABL1 transcript type influences response and outcome in <scp>P</scp>hiladelphia chromosomeâ€positive chronic myeloid leukemia patients treated frontline with imatinib. American Journal of Hematology, 2017, 92, 797-805.	4.1	71
15	Synergistic Cytotoxic Activity of Recombinant TRAIL Plus the Non-Genotoxic Activator of the p53 Pathway Nutlin-3 in Acute Myeloid Leukemia Cells. Current Drug Metabolism, 2007, 8, 395-403.	1.2	69
16	Managing chronic myeloid leukemia for treatment-free remission: a proposal from the GIMEMA CML WP. Blood Advances, 2019, 3, 4280-4290.	5.2	66
17	Caspofungin as first line therapy of pulmonary invasive fungal infections in 32 immunocompromised patients with hematologic malignancies. European Journal of Haematology, 2005, 75, 227-233.	2.2	64
18	Digital PCR improves the quantitation of DMR and the selection of CML candidates to TKIs discontinuation. Cancer Medicine, 2019, 8, 2041-2055.	2.8	63

#	Article	IF	Citations
19	Baseline factors associated with response to ruxolitinib: an independent study on 408 patients with myelofibrosis. Oncotarget, 2017, 8, 79073-79086.	1.8	63
20	Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia. Hematological Oncology, 2013, 31, 103-109.	1.7	59
21	Adherence and future discontinuation of tyrosine kinase inhibitors in chronic phase chronic myeloid leukemia. A patient-based survey on 1133 patients. Leukemia Research, 2015, 39, 1055-1059.	0.8	57
22	Chronic myeloid leukemia management at the time of the COVID-19 pandemic in Italy. A campus CML survey. Leukemia, 2020, 34, 2260-2261.	7.2	57
23	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-Â: 5-year outcome. Haematologica, 2008, 93, 770-774.	3.5	53
24	Functional regulation of the apurinic/apyrimidinic endonuclease 1 by nucleophosmin: impact on tumor biology. Oncogene, 2014, 33, 2876-2887.	5.9	52
25	Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood, 2013, 121, 5138-5144.	1.4	49
26	Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients. Hematological Oncology, 2018, 36, 561-569.	1.7	46
27	Next-generation sequencing for BCR-ABL1 kinase domain mutation testing in patients with chronic myeloid leukemia: a position paper. Journal of Hematology and Oncology, 2019, 12, 131.	17.0	45
28	The sorafenib plus nutlin-3 combination promotes synergistic cytotoxicity in acute myeloid leukemic cells irrespectively of FLT3 and p53 status. Haematologica, 2012, 97, 1722-1730.	3.5	44
29	Potential Pathogenetic Implications of Cyclooxygenase-2 Overexpression in B Chronic Lymphoid Leukemia Cells. American Journal of Pathology, 2005, 167, 1599-1607.	3.8	43
30	Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors. Haematologica, 2013, 98, 399-403.	3.5	42
31	The MDM-2 Antagonist Nutlin-3 Promotes the Maturation of Acute Myeloid Leukemic Blasts. Neoplasia, 2007, 9, 853-861.	5.3	41
32	Ruxolitinib discontinuation syndrome: incidence, risk factors, and management in 251 patients with myelofibrosis. Blood Cancer Journal, 2021, 11, 4.	6.2	41
33	Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia. Haematologica, 2015, 100, 1146-1150.	3.5	39
34	The role of MDR-related proteins in the prognosis of adult acute myeloid leukaemia (AML) with normal karyotype. Hematological Oncology, 2007, 25, 38-43.	1.7	37
35	Clinical impact of CD200 expression in patients with acute myeloid leukemia and correlation with other molecular prognostic factors. Oncotarget, 2015, 6, 30212-30221.	1.8	37
36	Gemtuzumab-ozogamicin in combination with fludarabine, cytarabine, idarubicin (FLAI-GO) as induction therapy in CD33-positive AML patients younger than 65 years. Leukemia Research, 2008, 32, 1800-1808.	0.8	36

#	Article	IF	Citations
37	Fludarabine-based induction therapy does not overcome the negative effect of ABCG2 (BCRP) over-expression in adult acute myeloid leukemia patients. Leukemia Research, 2010, 34, 942-945.	0.8	36
38	Imatinib in Very Elderly Patients with Chronic Myeloid Leukemia in Chronic Phase: A Retrospective Study. Drugs and Aging, 2013, 30, 629-637.	2.7	36
39	Health-related quality of life of newly diagnosed chronic myeloid leukemia patients treated with first-line dasatinib versus imatinib therapy. Leukemia, 2020, 34, 488-498.	7.2	35
40	Nilotinib and donor lymphocyte infusion in the treatment of Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL) relapsing after allogeneic stem cell transplantation and resistant to imatinib. Leukemia Research, 2009, 33, 174-177.	0.8	34
41	Role of the RANKL/RANK system in the induction of interleukin-8 (IL-8) in B chronic lymphocytic leukemia (B-CLL) cells. Journal of Cellular Physiology, 2006, 207, 158-164.	4.1	33
42	Pleural effusion and molecular response in dasatinib-treated chronic myeloid leukemia patients in a real-life Italian multicenter series. Annals of Hematology, 2018, 97, 95-100.	1.8	32
43	Testing Sokal's and the new prognostic score for chronic myeloid leukaemia treated with alpha-interferon. British Journal of Haematology, 2000, 111, 587-595.	2.5	31
44	Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. Leukemia Research, 2014, 38, 1173-1176.	0.8	30
45	Endogenous endophthalmitis following disseminated fungemia due to Fusarium solani in a patient with acute myeloid leukemia. European Journal of Haematology, 2002, 68, 314-317.	2.2	29
46	Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65â€ƒyr treated with induction regimens including fludarabine: retrospective analysis of 224 cases. European Journal of Haematology, 2008, 81, 354-363.	2.2	29
47	Tyrosine kinase inhibitors for elderly chronic myeloid leukemia patients: A systematic review of efficacy and safety data. Critical Reviews in Oncology/Hematology, 2012, 84, 93-100.	4.4	29
48	Managing chronic myeloid leukaemia in the elderly with intermittent imatinib treatment. Blood Cancer Journal, 2015, 5, e347-e347.	6.2	29
49	Efficacy and safety of ruxolitinib in intermediateâ€1 IPSS risk myelofibrosis patients: Results from an independent study. Hematological Oncology, 2018, 36, 285-290.	1.7	29
50	Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia. Annals of Hematology, 2002, 81, 462-466.	1.8	28
51	Treatment of Philadelphia-Positive Chronic Myeloid Leukemia with Imatinib: Importance of a Stable Molecular Response. Clinical Cancer Research, 2009, 15, 1059-1063.	7.0	28
52	Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. Leukemia Research, 2011, 35, 1164-1169.	0.8	28
53	Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells. Journal of Cellular Physiology, 2005, 205, 246-252.	4.1	26
54	BAALC overexpression retains its negative prognostic role across all cytogenetic risk groups in acute myeloid leukemia patients. American Journal of Hematology, 2013, 88, 848-852.	4.1	26

#	Article	IF	Citations
55	Frontline Dasatinib Treatment in a â€œReal-Lifeâ€•Cohort of Patients Older than 65 Years with Chronic Myeloid Leukemia. Neoplasia, 2016, 18, 536-540.	5.3	24
56	Differences in presenting features, outcome and prognostic models in patients with primary myelofibrosis and post-polycythemia vera and/or post-essential thrombocythemia myelofibrosis treated with ruxolitinib. New perspective of the MYSEC-PM in a large multicenter studyâŽ. Seminars in Hematology, 2018, 55, 248-255.	3.4	24
57	â€œVariantâ€specific discrepancy when quantitating BCRâ€ABL1 e13a2 and e14a2 transcripts using the Europe Against Cancer qPCR assay.â€•Is dPCR the key?. European Journal of Haematology, 2019, 103, 272-273.	2.2	24
58	Imatinib and polypharmacy in very old patients with chronic myeloid leukemia: effects on response rate, toxicity and outcome. Oncotarget, 2016, 7, 80083-80090.	1.8	24
59	Epstein-Barr virus reactivation in a patient treated with anti-thymocyte globulin for severe aplastic anemia. American Journal of Hematology, 2006, 81, 355-357.	4.1	23
60	The Oncogene DEK Promotes Leukemic Cell Survival and Is Downregulated by both Nutlin-3 and Chlorambucil in B-Chronic Lymphocytic Leukemic Cells. Clinical Cancer Research, 2010, 16, 1824-1833.	7.0	23
61	Durability of spleen response affects the outcome of ruxolitinib-treated patients with myelofibrosis: Results from a multicentre study on 284 patients. Leukemia Research, 2018, 74, 86-88.	0.8	23
62	The role of allogeneic stem-cell transplant in myelofibrosis in the era of JAK inhibitors: a case-based review. Bone Marrow Transplantation, 2020, 55, 708-716.	2.4	23
63	WT1 transcript amount discriminates secondary or reactive eosinophilia from idiopathic hypereosinophilic syndrome or chronic eosinophilic leukemia. Leukemia, 2007, 21, 1442-1450.	7.2	22
64	Nilotinib 300 mg twice daily: an academic single-arm study of newly diagnosed chronic phase chronic myeloid leukemia patients. Haematologica, 2016, 101, 1200-1207.	3.5	22
65	Healthâ€related quality of life in patients with chronic myeloid leukemia receiving firstâ€line therapy with nilotinib. Cancer, 2018, 124, 2228-2237.	4.1	22
66	Cryptic BCR-ABL fusion gene as variant rearrangement in chronic myeloid leukemia: molecular cytogenetic characterization and influence on TKIs therapy. Oncotarget, 2017, 8, 29906-29913.	1.8	22
67	Concomitant ABCG2 overexpression and FLT3â€ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse. Cancer, 2011, 117, 2156-2162.	4.1	21
68	Q141K polymorphism of ABCG2 protein is associated with poor prognosis in adult acute myeloid leukemia treated with idarubicin-based chemotherapy. Haematologica, 2013, 98, e28-e29.	3.5	21
69	Systematic Evaluation of Hypereosinophilic Syndrome-Related Organ Damage According to FIP1L1-PDGFRA Status and Response to the Therapy: Analysis from Prospective Clinical Trial with Imatinib Mesylate.. Blood, 2007, 110, 3557-3557.	1.4	21
70	Case?control study of multidrug resistance phenotype and response to induction treatment including or not fludarabine in newly diagnosed acute myeloid leukaemia patients. British Journal of Haematology, 2007, 136, 87-95.	2.5	20
71	COVIDâ€19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. British Journal of Haematology, 2022, 196, 559-565.	2.5	20
72	High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients. Leukemia Research, 2017, 58, 31-38.	0.8	19

#	Article	IF	Citations
73	Second primary malignancy in myelofibrosis patients treated with ruxolitinib. British Journal of Haematology, 2021, 193, 356-368.	2.5	19
74	High and Early Rates of Cytogenetic and Molecular Response with Nilotinib 800 Mg Daily as First Line Treatment of Ph-Positive Chronic Myeloid Leukemia in Chronic Phase: Results of a Phase 2 Trial of the GIMEMA CML Working Party. Blood, 2008, 112, 181-181.	1.4	19
75	The impact of comorbidity on health-related quality of life in elderly patients with chronic myeloid leukemia. Annals of Hematology, 2016, 95, 211-219.	1.8	18
76	Brain natriuretic peptide level as marker of cardiac function in imatinibâ€"Treated chronic myeloid leukemia patients: No evidence of cardiotoxicity of imatinib therapy. American Journal of Hematology, 2008, 83, 517-518.	4.1	17
77	Nutlin-3 Downregulates the Expression of the Oncogene TCL1 in Primary B Chronic Lymphocytic Leukemic Cells. Clinical Cancer Research, 2011, 17, 5649-5655.	7.0	17
78	Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline. Annals of Hematology, 2019, 98, 2329-2338.	1.8	17
79	Predictive Factors of Stable Deep Molecular Response in Chronic Myeloid Leukemia Patients Treated with Imatinib Standard Dose: A Study from the Gruppo Triveneto LMC. Blood, 2015, 126, 597-597.	1.4	17
80	<scp>ABCG</scp>2 overexpression in patients with acute myeloid leukemia: Impact on stem cell transplantation outcome. American Journal of Hematology, 2015, 90, 784-789.	4.1	16
81	Novel type of BCR-ABL transcript in a chronic myelogenous leukaemia patient relapsed after bone marrow transplantation. SHORT REPORT. British Journal of Haematology, 2000, 111, 644-646.	2.5	16
82	Incidence of second primary malignancies and related mortality in patients with imatinib-treated chronic myeloid leukemia. Haematologica, 2017, 102, 1530-1536.	3.5	15
83	Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Realâ€world data. Hematological Oncology, 2020, 38, 372-380.	1.7	15
84	Imatinib therapy for chronic myeloid leukemia patients who relapse after allogeneic stem cell transplantation: a molecular analysis. Bone Marrow Transplantation, 2007, 39, 189-191.	2.4	14
85	Combined treatment of CpG-oligodeoxynucleotide with Nutlin-3 induces strong immune stimulation coupled to cytotoxicity in B-chronic lymphocytic leukemic (B-CLL) cells. Journal of Leukocyte Biology, 2008, 83, 434-437.	3.3	14
86	Long term outcome of Ph+ CML patients achieving complete cytogenetic remission with interferon based therapy moving from interferon to imatinib era. American Journal of Hematology, 2014, 89, 119-124.	4.1	14
87	How could patient reported outcomes improve patient management in chronic myeloid leukemia?. Expert Review of Hematology, 2017, 10, 9-14.	2.2	14
88	Safety and efficacy of switching from branded to generic imatinib in chronic phase chronic myeloid leukemia patients treated in Italy. Leukemia Research, 2018, 74, 75-79.	0.8	14
89	Ruxolitinib rechallenge in resistant or intolerant patients with myelofibrosis: Frequency, therapeutic effects, and impact on outcome. Cancer, 2021, 127, 2657-2665.	4.1	14
90	Low-density lipoprotein (LDL) levels and risk of arterial occlusive events in chronic myeloid leukemia patients treated with nilotinib. Annals of Hematology, 2021, 100, 2005-2014.	1.8	14

#	Article	IF	Citations
91	Excellent Outcomes at 3 Years with Nilotinib 800 Mg Daily In Early Chronic Phase, Ph+ Chronic Myeloid Leukemia (CML): Results of a Phase 2 GIMEMA CML WP Clinical Trial. Blood, 2010, 116, 359-359.	1.4	14
92	Plasma Cell Leukemia Occurring in a Patient with Thrombocythemia Treated with Hydroxyurea and Busulphan. Leukemia and Lymphoma, 2004, 45, 821-824.	1.3	13
93	Evaluation of residual CD34⁺Ph⁺ progenitor cells in chronic myeloid leukemia patients who have complete cytogenetic response during firstâ€line nilotinib therapy. Cancer, 2012, 118, 5265-5269.	4.1	13
94	Efficacy and safety of bosutinib in chronic phase CML patients developing pleural effusion under dasatinib therapy. Annals of Hematology, 2019, 98, 2609-2611.	1.8	13
95	Tracing the decision-making process for myelofibrosis: diagnosis, stratification, and management of ruxolitinib therapy in real-word practice. Annals of Hematology, 2020, 99, 65-72.	1.8	13
96	The serological prevalence of SARSâ€CoVâ€2 infection in patients with chronic myeloid leukemia is similar to that in the general population. Cancer Medicine, 2021, 10, 6310-6316.	2.8	13
97	Excellent outcomes of 2G-TKI therapy after imatinib failure in chronic phase CML patients. Oncotarget, 2018, 9, 14219-14227.	1.8	13
98	Biological and clinical features of T-biphenotypic acute leukaemia: report from a single centre. British Journal of Haematology, 2004, 125, 814-815.	2.5	12
99	Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia. Annals of Hematology, 2013, 92, 179-183.	1.8	12
100	A phase II study of Î±-interferon and oral arabinosyl cytosine (YNK01) in chronic myeloid leukemia. Leukemia, 2003, 17, 554-559.	7.2	11
101	Differential gene expression induction by TRAIL in B chronic lymphocytic leukemia (B-CLL) cells showing high versus low levels of Zap-70. Journal of Cellular Physiology, 2007, 213, 229-236.	4.1	11
102	EUTOS score predicts long-term outcome but not optimal response to imatinib in patients with chronic myeloid leukaemia. Leukemia Research, 2013, 37, 1457-1460.	0.8	11
103	Splenectomy in Myelofibrosis: Indications, Efficacy, and Complications. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 588-595.	0.4	11
104	Rotation of nilotinib and imatinib for firstâ€line treatment of chronic phase chronic myeloid leukemia. American Journal of Hematology, 2016, 91, 617-622.	4.1	10
105	Intolerance to tyrosine kinase inhibitors in chronic myeloid leukemia: the possible role of ponatinib. Expert Opinion on Drug Safety, 2018, 17, 623-628.	2.4	10
106	Impact of comorbidities and body mass index in patients with myelofibrosis treated with ruxolitinib. Annals of Hematology, 2019, 98, 889-896.	1.8	10
107	Gimema Registry of Conception/Pregnancy in Adult Italian Patients Diagnosed with Chronic Myeloid Leukemia (CML): Report on 166 Outcomes. Blood, 2018, 132, 43-43.	1.4	10
108	Prognostic Value of BCR-ABL1 Transcript Type in Chronic Myeloid Leukemia Patients Treated Frontline with Nilotinib. Blood, 2016, 128, 3070-3070.	1.4	10

#	Article	IF	Citations
109	Treatment-Free Remission in Chronic Myeloid Leukemia Patients Treated With Low-Dose TKIs: A Feasible Option Also in the Real-Life. A Campus CML Study. Frontiers in Oncology, 2022, 12, 839915.	2.8	10
110	Donor compatibility and performance status affect outcome of allogeneic haematopoietic stem cell transplant in patients with relapsed or refractory acute myeloid leukaemia. Annals of Hematology, 2012, 91, 1937-1943.	1.8	9
111	Imatinib-treated Chronic Myeloid Leukemia patients with discordant response between cytogenetic and molecular tests at 3 and 6 month time-points have a reduced probability of subsequent optimal response. Haematologica, 2015, 100, e299-301.	3.5	9
112	Clinical factors predictive of myelofibrotic evolution in patients with polycythemia vera. Annals of Hematology, 2015, 94, 873-874.	1.8	9
113	Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicineâ€"Results from the Italian â€˜Back to Lifeâ€™ project. Quality of Life Research, 2018, 27, 1545-1554.	3.1	9
114	Renin angiotensin system inhibitors reduce the incidence of arterial thrombotic events in patients with hypertension and chronic myeloid leukemia treated with second- or third-generation tyrosine kinase inhibitors. Annals of Hematology, 2020, 99, 1525-1530.	1.8	9
115	Molecular response and quality of life in chronic myeloid leukemia patients treated with intermittent TKIs: First interim analysis of OPTkIMA study. Cancer Medicine, 2021, 10, 1726-1737.	2.8	9
116	Impact of comorbidities and body mass index on the outcome of polycythemia vera patients. Hematological Oncology, 2021, 39, 409-418.	1.7	9
117	Brain Natriuretic Peptide (BNP) Level as Marker of Cardiac Function in Imatinib - Treated Chronic Myeloid Leukemia Patients: No Evidence of Cardiotoxicity of Imatinib Therapy.. Blood, 2007, 110, 2948-2948.	1.4	9
118	What is the optimal dosage of valganciclovir as preemptive therapy for CMV infection in allogeneic hematopoietic SCT?. Bone Marrow Transplantation, 2008, 42, 207-208.	2.4	8
119	Histone post-translational modifications associated to BAALC expression in leukemic cells. Biochemical and Biophysical Research Communications, 2012, 417, 721-725.	2.1	8
120	EUTOS score predicts early optimal response to imatinib according to the revised 2013 ELN recommendations. Annals of Hematology, 2014, 93, 163-164.	1.8	8
121	ABCG2 and CD200 define patients at high risk of relapse in ELN favorable subgroup of AML. European Journal of Haematology, 2017, 99, 269-274.	2.2	8
122	Tyrosine Kinase Inhibitor Sequencing in Patients with Chronic Myeloid Leukemia. Oncology and Therapy, 2019, 7, 95-100.	2.6	8
123	The Use of EUTOS Long-Term Survival Score Instead of Sokal Score Is Strongly Advised in Elderly Chronic Myeloid Leukemia Patients. Blood, 2018, 132, 44-44.	1.4	8
124	Nilotinib 800 Mg Daily as Frontline Therapy of Ph + Chronic Myeloid Leukemia: Dose Delivered and Safety Profile for the GIMEMA CML Working Party.. Blood, 2009, 114, 2205-2205.	1.4	8
125	Abdominal abscess and Hafnia alvei septicemia occurring during the aplastic phase after autologous stem-cell transplantation in a patient with diffuse large B-cell lymphoma. Journal of Infection and Chemotherapy, 2004, 10, 303-306.	1.7	7
126	Two novel NPM1 mutations in a therapyâ€responder AML patient. Hematological Oncology, 2010, 28, 151-155.	1.7	7

#	Article	IF	Citations
127	The expression levels of the pro-apoptotic XAF-1 gene modulate the cytotoxic response to Nutlin-3 in B chronic lymphocytic leukemia. Leukemia, 2010, 24, 480-483.	7.2	7
128	Role of blood cells dynamism on hemostatic complications in low-risk patients with essential thrombocythemia. Internal and Emergency Medicine, 2015, 10, 451-460.	2.0	7
129	Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients. British Journal of Haematology, 2018, 183, 35-46.	2.5	7
130	Early CP CML, Nilotinib 400 mg Twice Daily Frontline: Beyond 3 Years, Results Remain Excellent and Stable (A GIMEMA CML Working Party Trial). Blood, 2011, 118, 2756-2756.	1.4	7
131	Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUXâ€ÐOL study. British Journal of Haematology, 2022, 197, 190-200.	2.5	7
132	Peripheral blasts are associated with responses to ruxolitinib and outcomes in patients with chronicâ€Þphase myelofibrosis. Cancer, 2022, 128, 2449-2454.	4.1	7
133	Low low-density lipoprotein (LDL), cholesterol and triglycerides plasma levels are associated with reduced risk of arterial occlusive events in chronic myeloid leukemia patients treated with ponatinib in the real-life. A Campus CML study. Blood Cancer Journal, 2020, 10, 66.	6.2	6
134	Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network. Frontiers in Oncology, 2021, 11, 739171.	2.8	6
135	Encouraging preliminary results in 12 patients with high-risk haematological malignancies by omitting graft-versus-host disease prophylaxis after allogeneic transplantation. British Journal of Haematology, 2000, 111, 662-667.	2.5	6
136	Asciminib as a new option in the treatment of chronic myeloid leukemia. Future Oncology, 2021, 17, 5003-5005.	2.4	6
137	Imatinib mesylate (Glivec) pre-treatment does not have a negative effect on outcome of allogenic hematopoietic stem cell transplantation in Philadelphia-positive leukemias. Bone Marrow Transplantation, 2004, 34, 827-828.	2.4	5
138	Efficacy and safety of ruxolitinib and hydroxyurea combination in patients with hyperproliferative myelofibrosis. Annals of Hematology, 2019, 98, 1933-1936.	1.8	5
139	Detection of Actionable BCR-ABL1 Kinase Domain (KD) Mutations in Chronic Myeloid Leukemia (CML) Patients with Failure and Warning Response to Tyrosine Kinase Inhibitors (TKIs): Potential Impact of Next-Generation Sequencing (NGS) and Droplet Digital PCR (ddPCR) on Clinical Decision Making. Blood, 2019, 134, 661-661.	1.4	5
140	Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement Can Be Effectively Treated with Imatinib.. Blood, 2004, 104, 1504-1504.	1.4	5
141	Five-Year Results of Nilotinib 400 Mg BID in Early Chronic Phase Chronic Myeloid Leukemia (CML): High Rate of Deep Molecular Response - Update of the Gimema CML WP Trial CML0307. Blood, 2012, 120, 3784-3784.	1.4	5
142	Making Treatment-Free Remission (TFR) Easier in Chronic Myeloid Leukemia: Fact-Checking and Practical Management Tools. Targeted Oncology, 2021, 16, 823-838.	3.6	5
143	Fungal and Bacterial Infections in Acute Myeloid Leukemia Patients Treated with Induction Regimens Including Fludarabine: A Retrospective Analysis of 224 Cases.. Blood, 2007, 110, 4351-4351.	1.4	5
144	Long Term Follow-up of Ph+ CML Patients Achieving Complete Cytogenetic Response (CCgR) with Interferon Based Therapy - GIMEMA Protocol CML0509. Blood, 2011, 118, 786-786.	1.4	5

#	Article	IF	Citations
145	Unexpected phenotype of a typical NPM1 mutant. British Journal of Haematology, 2009, 147, 760-763.	2.5	4
146	ABCG2, Cytogenetics, and Age Predict Relapse after Allogeneic Stem Cell Transplantation for Acute Myeloid Leukemia in Complete Remission. Biology of Blood and Marrow Transplantation, 2016, 22, 1621-1626.	2.0	4
147	Chronic Myeloid Leukemia Italian Multicenter Observational Study (CML-IT-MOS): Clinical Characteristics of Chronic Myeloid Leukemia (CML) Patients Treated in Real-Life between 2012 and 2016 in 66 Italian Hematology Centers of the Gimema Study Group. Blood, 2018, 132, 45-45.	1.4	4
148	Frequency, Distribution and Prognostic Value of ABL Kinase Domain (KD) Mutations in Different Subsets of Philadelphia-Positive (Ph+) Patients (Pts) Resistant to Imatinib (IM) by the Gimema Working Party on CML.. Blood, 2005, 106, 435-435.	1.4	4
149	Predictors for Response to Ruxolitinib in Real-Life: An Observational Independent Study on 408 Patients with Myelofibrosis. Blood, 2016, 128, 1128-1128.	1.4	4
150	Factors affecting outcome of allogeneic stem cell transplantation as salvage in patients with acute myeloid leukemia primary refractory to intensive induction therapy. American Journal of Hematology, 2014, 89, 933-934.	4.1	3
151	Long-term efficacy and safety of nilotinib therapy after imatinib failure in eosinophilic myeloproliferative neoplasm and ETV6-ABL rearrangement. Annals of Hematology, 2015, 94, 1423-1424.	1.8	3
152	Impact of 2016 WHO diagnosis of early and overt primary myelofibrosis on presentation and outcome of 232 patients treated with ruxolitinib. Hematological Oncology, 2019, 37, 418-423.	1.7	3
153	Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study. Leukemia, 2021, 35, 1814-1816.	7.2	3
154	Outcome of 472 Chronic Myeloid Leukemia Patients Treated with Frontline Nilotinib: A Gimema CML WP Analysis. Blood, 2018, 132, 458-458.	1.4	3
155	Ten-Year Follow-up of Patients with Chronic Myeloid Leukemia Treated with Nilotinib in First-Line: Final Results of the Gimema CML 0307 Trial. Blood, 2019, 134, 4145-4145.	1.4	3
156	Phase II Multicentric Explorative Study of Intermittent Imatinib (IM) Treatment (INTERIM) in Elderly Patients with Ph+ Chronic Myeloid Leukemia (CML) Who Achieved a Stable Complete Cytogenetic Response (CCgR) with Standard IM Therapy.. Blood, 2009, 114, 860-860.	1.4	3
157	FIP1L1-PDGFRalpha Positive Hypereosinophilic Syndrome (HES). The Response to Imatinib (IM) Is Durable. A Report of 21 Patients with a Follow-Up of 12 to 67 Months.. Blood, 2006, 108, 2700-2700.	1.4	3
158	Imatinib-Treated CML Patients With Discordant Response Between Cytogenetic and Molecular Tests At 3 and 6 Month Timepoints Have a Reduced Probability Of Subsequent Optimal Response: A Study From The â€œGruppo Triveneto LMCâ€• Blood, 2013, 122, 2732-2732.	1.4	3
159	BCL-2 Expression in AML Patients over 65 Years: Impact on Outcomes across Different Therapeutic Strategies. Journal of Clinical Medicine, 2021, 10, 5096.	2.4	3
160	Reply to Pfirrmann and Hasford. British Journal of Haematology, 2001, 114, 241-242.	2.5	2
161	Effect of amifostine on the cytotoxicity of daunorubicin and daunoxome in tumor and normal cells. Cancer Chemotherapy and Pharmacology, 2006, 57, 517-524.	2.3	2
162	FLAIE (fludarabine, cytarabine, idarubicin, and etoposide), a four drug induction chemotherapy for adult acute myeloid leukemia: A single center experience. American Journal of Hematology, 2009, 84, 690-692.	4.1	2

#	Article	IF	Citations
163	Reduced expression of cell cycleâ€associated genes in B lymphocytes purified from the peripheral blood of earlyâ€stage B chronic lymphocytic leukaemia patients. British Journal of Haematology, 2009, 145, 424-426.	2.5	2
164	Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?. Leukemia Research, 2018, 74, 55-56.	0.8	2
165	Molecular landscape in adult acute myeloid leukemia: where we are where we going?. Journal of Laboratory and Precision Medicine, 0, 4, 17-17.	1.1	2
166	mpact of Concomitant Aberrant CD200 and BCL2 Overexpression on Outcome of Acute Myeloid Leukemia: A Cohort Study from a Single Center. Turkish Journal of Haematology, 2021, 38, 119-125.	0.5	2
167	Long term follow-up of frontline Dasatinib in older patients with chronic myeloid leukemia in chronic phase treated outside clinical trials: a real-life cohort observational study. Acta OncolÃ³gica, 2021, 60, 1527-1533.	1.8	2
168	Single nucleotide polymorphisms of the factor IX gene for linkage analysis in the southern Chinese population. British Journal of Haematology, 2000, 111, 540-543.	2.5	2
169	Concomitant Treatment with Ruxolitinib and Deferasirox in the Management of Iron Overload in Patients with Myelofibrosis: A Multicenter Italian Experience. Blood, 2019, 134, 839-839.	1.4	2
170	Do Not Miss Karyotyping at Chronic Myeloid Leukemia Diagnosis: An Italian Campus CML Study on the Role of Complex Variant Translocations. Blood, 2020, 136, 43-44.	1.4	2
171	Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML. Blood, 2010, 116, 2293-2293.	1.4	2
172	Evaluation of Residual CD34+/Ph+ Stem Cells In Chronic Myeloid Leukemia Patients In Complete Cytogenetic Response during First Line Nilotinib Therapy.. Blood, 2010, 116, 3413-3413.	1.4	2
173	Dissecting the Complexity of Philadelphia-Positive Mutated Populations by Ultra-Deep Sequencing of the Bcr-Abl Kinase Domain: Biological and Clinical Implications. Blood, 2012, 120, 692-692.	1.4	2
174	Frontline Treatment With Imatinib Mesylate in Chronic Myeloid Leukemia Patients in Early Chronic Phase: a Very Long-Term Analysis by the GIMEMA CML Working Party. Blood, 2013, 122, 258-258.	1.4	2
175	Long-Term Outcome to First-Line Imatinib according to 2013 European LeukemiaNet Response Criteria: a GIMEMA CML WP Analysis. Blood, 2015, 126, 2792-2792.	1.4	2
176	Efficacy and Safety of Ruxolitinib in Elderly Patients (> 75 years) with Myelofibrosis. Blood, 2016, 128, 4251-4251.	1.4	2
177	Peripheral Blood Flow-Cytometry Chronic Myeloid Leukemia Stem Cells Detection and Quantification during Tyrosine Kinase Inhibitors Therapy. Blood, 2016, 128, 942-942.	1.4	2
178	Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib.. Blood, 2012, 120, 2797-2797.	1.4	2
179	Clinical Outcomes Under Hydroxyurea and Impact of ELN Responses in Patients with Polycythemia Vera: A PV-NET Real World Study. Blood, 2019, 134, 4174-4174.	1.4	2
180	Management of Myelofibrosis during Treatment with Ruxolitinib: A Real-World Perspective in Case of Resistance and/or Intolerance. Current Oncology, 2022, 29, 4970-4980.	2.2	2

#	Article	IF	Citations
181	Combination of EUTOS score and 3-month BCR-ABL transcript level identifies a group of good-risk chronic myeloid leukemia patients with favorable response to frontline imatinib therapy. American Journal of Hematology, 2015, 90, E135-E137.	4.1	1
182	Impact of fludarabineâ€based induction therapy on outcome of <scp>FLT</scp>3â^'/<scp>NPM</scp>1+ cytogenetically normal acute myeloid leukemia. American Journal of Hematology, 2017, 92, E45-E47.	4.1	1
183	Impact of Arterial Thrombotic Events on the Outcome of Chronic Myeloid Leukemia Patients Treated with Nilotinib First-Line: A GIMEMA CML WP Analysis. Clinical Lymphoma, Myeloma and Leukemia, 2017, 17, S313-S314.	0.4	1
184	The significance of early warning in chronic myeloid leukemia. Expert Review of Hematology, 2018, 11, 265-266.	2.2	1
185	Comparative Monitoring of Minimal Residual Disease (MRD) By RT-Quantitative (RT-qPCR) and Digital PCR (dPCR) in Ph+ Chronic Myeloid Leukemia (CML) Patients Treated with TKIs for Recognition of Stable Deep Molecular Response (DMR) and Identification of Best Candidates to TKIs Treatment Discontinuation. Blood, 2018, 132, 3012-3012.	1.4	1
186	One Size Does Not Fit to All: Intolerant or Resistant CML Patients Could Benefit from Different Ponatinib Starting Dose Strategies. Multicenter Italian Experience. Blood, 2018, 132, 1732-1732.	1.4	1
187	Determinants of Choice of Front-Line Tyrosine Kinase Inhibitor for Chronic Phase CML: A Study from the "Registro Italiano LMC & Campus CML". Blood, 2020, 136, 35-36.	1.4	1
188	Chronic Eosinophilic Leukaemia (CEL) with FIP1L1-PDGFRalpha Rearrangement (F/P): The Response to Imatinib (IM) Is Durable. A Report of 33 Patients with A Follow â€“up of 30 to 92 Months.. Blood, 2009, 114, 3894-3894.	1.4	1
189	Imatinib in Very Elderly (> 75 years) CML Patients: Are Low-Doses (<400 mg daily) Enough?. Blood, 2011, 118, 2770-2770.	1.4	1
190	Alternating Nilotinib 400 mg twice daily and Imatinib 400 mg once daily as Frontline Treatment of Ph+ Chronic Myeloid Leukemia. A Phase 2 Multicentric Study of the GIMEMA CML Working Party. Blood, 2011, 118, 453-453.	1.4	1
191	Clinical Factors Predictive Of Myelofibrotic Evolutions In Patients With Essential Thrombocythemia and Polycythemia Vera. Blood, 2013, 122, 4082-4082.	1.4	1
192	Impact of Age on Efficacy, Safety, and Long-Term Outcome of Chronic Myeloid Leukemia (CML) Patients Treated in First-Line with Nilotinib: An Analysis of the Gimema CML Working Party. Blood, 2016, 128, 3068-3068.	1.4	1
193	The Quantitative Assessment of WT1 Allows To Distinguish between Primary and Secondary or Reactive Hypereosinophilia.. Blood, 2005, 106, 3251-3251.	1.4	1
194	Old Age Affects Survival but Not Response in Philadelphia Positive (Ph+) Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib (IM): A Study of the GIMEMA CML WORKING PARTY.. Blood, 2009, 114, 1118-1118.	1.4	1
195	Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs. Blood, 2010, 116, 2294-2294.	1.4	1
196	Updating Long-Term Outcome of Intermittent Imatinib (INTERIM) Treatment in Elderly Patients with Ph+-CML. Blood, 2014, 124, 1794-1794.	1.4	1
197	Impact of Comorbidities and Body Mass Index in Patients with Polycythemia Vera: A PV-NET Real World Study. Blood, 2019, 134, 4184-4184.	1.4	1
198	Choice of Frontline Tyrosine-Kinase Inhibitor in Very Elderly Patients with Chronic Myeloid Leukemia: A "Campus CML" Study. Blood, 2021, 138, 3617-3617.	1.4	1

#	Article	IF	Citations
199	Efficacy and Safety of Ruxolitinib in the Treatment of Elderly Patients with Policythemia Vera Resistant/Intolerant to Hydroxyurea. Blood, 2021, 138, 2581-2581.	1.4	1
200	BCR-ABL1 Levels at First Month after TKI Discontinuation Predict Subsequent Maintenance of Treatment-Free Remission: A Study from the "Gruppo Triveneto LMC". Blood, 2020, 136, 9-10.	1.4	1
201	Differential Treatment Strategy in Polycythemia Vera Patients with Stable Suboptimal Response to Hydroxyurea: Clinical Correlations and Impact on Survival. Blood, 2020, 136, 17-18.	1.4	1
202	Sequential Treatments in Chronic Phase Chronic Myeloid Leukemia (CML) Patients without Optimal Response after Frontline Nilotinib or Dasatinib: An Italian CML Campus Study. Blood, 2020, 136, 45-46.	1.4	1
203	Serological Prevalence of Sars-Cov-2 Infection Among Chronic Myeloid Leukemia Patients Undergoing Tyrosine Kinase Inhibitor Treatment in Italy (COVID-19-HEM Study). Blood, 2020, 136, 42-42.	1.4	1
204	Novel type of BCRâ€“ABL transcript in a chronic myelogenous leukaemia patient relapsed after bone marrow transplantation. British Journal of Haematology, 2000, 111, 644-646.	2.5	0
205	Screening of Bcr-Abl Transcripts in Philadelphia Negative Essential Thrombocythemia. Leukemia and Lymphoma, 2000, 39, 339-341.	1.3	0
206	Nocardiosis with Favourable Clinical Outcome in Progressive B-chronic Lymphocytic Leukaemia. Leukemia and Lymphoma, 2002, 43, 1893-1894.	1.3	0
207	Overcoming therapy failure in elderly patients with chronic myeloid leukemia. International Journal of Hematologic Oncology, 2014, 3, 353-365.	1.6	0
208	Russo D, Martinelli G, Malagola M, et al. Effects and outcome of a policy of intermittent imatinib treatment in elderly patients with chronic myeloid leukemia. Blood. 2013;121(26):5138-5144.. Blood, 2014, 123, 2902-2902.	1.4	0
209	ABCG2 overexpression and deoxyadenosine analogue activity in acute myeloid leukemia. Cancer, 2017, 123, 4934-4935.	4.1	0
210	CD200 in hematological malignancies: just a diagnostic tool or more?. Journal of Laboratory and Precision Medicine, 2017, 2, 77-77.	1.1	0
211	CML-206: ReSETting SETD2/H3K36Me3 Deficiency as a New Therapeutic Strategy in Blast Crisis Chronic Myeloid Leukemia Patients. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, S236-S237.	0.4	0
212	Haploidentical transplant after failure of a first allogeneic transplant: A long and winding road. European Journal of Haematology, 2021, 106, 871-872.	2.2	0
213	Imatinib Therapy for Chronic Myeloid Leukemia Patients Who Relapse after Allogeneic Stem Cell Transplantation: A Molecular Analysis.. Blood, 2004, 104, 4655-4655.	1.4	0
214	Aberrant Expression of Trail in B Chronic Lymphocytic Leukemia (B-CLL) Cells.. Blood, 2005, 106, 4976-4976.	1.4	0
215	A Novel Denaturing-High Performance Liquid Chromatography (D-HPLC)-Based Method for Kit Mutation Screening of Patients (pts) with Systemic Mastocytosis (SM) Allows the Identification of Unreported Kit Variants.. Blood, 2006, 108, 4849-4849.	1.4	0
216	Gemtuzumab-Ozogamicin in Combination with Fludarabine, Cytarabine, Idarubicin (FLAI-GO) as Induction Therapy in CD33-Positive AML patients Younger Than 65 Years. Report of a Multicentric Trial. Blood, 2008, 112, 3998-3998.	1.4	0

#	Article	IF	Citations
217	Extreme Variability of FIP1L1-PDGFRalpha Transcripts Do Not Influence to Imatinib Mesylate Response in CEL: Clinical Follow-up and Molecular Analysis of the Italian Multicenter Prospective Study. Blood, 2008, 112, 5223-5223.	1.4	0
218	Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib.. Blood, 2009, 114, 2211-2211.	1.4	0
219	First Line Treatment with Nilotinib 800 Mg Daily Results In Unprecedentedly High Rate of Rapid, â€œDeepâ€• and Stable Molecular Responses as Assessed by a High Sensitive Nanofluidic Array for the Detection of Rare Copies of BCR-ABL1 Transcript: Results of a Phase 2 Trial of the GIMEMA CML Working Party. Blood, 2010, 116, 2720-2720.	1.4	0
220	Bcr-Abl Kinase Domain Mutations in Imatinib and in Second-Generation Tyrosine Kinase Inhibitor Eras: Seven Years of Mutation Analysis, a Report by the GIMEMA CML Working Party. Blood, 2010, 116, 2279-2279.	1.4	0
221	Q141K Polymorphism of ABCG2 Protein Is Associated with Poor Prognosis In Adult Acute Myeloid Leukemia Treated with a Idarubicin-Based Chemotherapy Protocol. Blood, 2010, 116, 4941-4941.	1.4	0
222	Incidence and Mortality of Second Malignancies In 559 Patients with Chronic Myeloid Leukemia (CML) Treated with Imatinib Frontline: Data From the GIMEMA CML Working Party. Blood, 2010, 116, 2281-2281.	1.4	0
223	One Year of Intermittent Imatinib (IM) Treatment (InterIM) Maintains the Complete Cytogenetic Response (CCgR) Previously Achieved with Standard IM Therapy In Elderly (â‰¥ 65 years) Ph+ CML Patients â€“ EudraCT Number 2007â€“005102-42, ClinicalTrials.Gov NCT 00858806.. Blood, 2010, 116, 3412-3412.	1.4	0
224	Health-Related Quality of Life In Patients with Chronic Myeloid Leukemia Undergoing First Line Treatment with Imatinib for at Least Three Years Compared with the General Population. A Multicenter Study Including 448 Patients. Blood, 2010, 116, 2273-2273.	1.4	0
225	Imatinib In Very Elderly CML Patients: What Can We Achieve?.. Blood, 2010, 116, 1229-1229.	1.4	0
226	Intermittent Imatinib (INTERIM) Treatment of Patients with Ph+ Chronic Myeloid Leukemia in Complete Cytogenetic Response: Cytogenetic and Molecular Data At One Year. Blood, 2011, 118, 1682-1682.	1.4	0
227	Drug Resistance and Bcr-Abl Kinase Domain Mutations In Philadelphia-Positive Acute Lymphoblastic Leukemia From the Imatinib to the 2nd-Generation Tyrosine Kinase Inhibitor Era: The Main Changes Are In the Type of Mutations, but Not In the Frequency of Mutation Involvement. Blood, 2011, 118, 575-575.	1.4	0
228	Investigating Personal and Treatment Related Factors Associated with Adherence Behavior in Patients with Chronic Myeloid Leukemia Receiving Long Term Imatinib Therapy. Blood, 2011, 118, 1026-1026.	1.4	0
229	Moderate/ Severe Pleural Effusion As a Side Effect in Very Old Chronic Myeloid Leukemia (CML) Patients Undergoing Imatinib Treatment. Blood, 2011, 118, 4445-4445.	1.4	0
230	APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS. Blood, 2011, 118, 1686-1686.	1.4	0
231	BCR-ABL kinase domain mutations and resistance in Ph+ acute lymphoblastic leukemia from the imatinib to the second-generation TKI era.. Journal of Clinical Oncology, 2012, 30, 6531-6531.	1.6	0
232	Blood Cells Dynamic and Thrombo-Haemorragic Events in Low Risk Essential Thrombocytosis Patients. A North Italian and Austrian Study.. Blood, 2012, 120, 2839-2839.	1.4	0
233	4-Year Outcome Of 215 Patients With Newly Diagnosed Chronic Myeloid Leukemia (CML) Treated Frontline With Nilotinib In Investigator-Sponsored Studies. A Report From The Gimema CML Working Party. Blood, 2013, 122, 4000-4000.	1.4	0
234	EUTOS Score Predicts Optimal Response To Imatinib According To The Revised ELN Recommendations Better Than Sokal Score: A Study From The â€œGruppo Triveneto LMCâ€• Blood, 2013, 122, 4024-4024.	1.4	0

#	Article	IF	Citations
235	Deep Molecular Response to Nilotinib As First-Line Treatment of BCR-ABL+ CML in Early Chronic Phase: A Phase 3b Multicenter Study of the Gimema CML Working Party. Blood, 2014, 124, 4532-4532.	1.4	0
236	Very Elderly Patients with Chronic Phase-Chronic Myeloid Leukemia on Imatinib: No Impact of Concomitant Drugs on Complete Cytogenetic Response. Blood, 2015, 126, 1582-1582.	1.4	0
237	Prospective Metabolic and Cardiovascular Assessment in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib 300 Mg Bid Frontline in the Gimema 0811 Trial. Blood, 2015, 126, 4046-4046.	1.4	0
238	Long-Term Follow-up in Very Elderly Patients with Chronic Myeloid Leukemia Treated with Imatinib Frontline. Blood, 2015, 126, 1598-1598.	1.4	0
239	Digital PCR (dPCR) Overcomes the Limitations in Detection and in Quantification of Quantitative PCR (qPCR) and Reveals Different Levels of BCR-ABL1 Copies/Âµl Among the Chronic Myeloid Leukemia (CML) Patients Achieving Major (MR3.0) or DEEP (MR4.0, MR4.5 and MR5.0) Molecular Response with Tyrosin Kynase Inhibitors (TKIs). Blood, 2015, 126, 4028-4028.	1.4	0
240	Similar Efficacy of Dasatinib and Nilotinib As Second-Line Therapy in Patients with Chronic Phase Chronic Myeloid Leukemia Failing Imatinib: A Retrospective, Real-Life Study. Blood, 2016, 128, 5434-5434.	1.4	0
241	Impact of Comorbidities and Body Mass Index in Myelofibrosis Patients Treated with Ruxolitinib: A Retrospective Analysis. Blood, 2016, 128, 5464-5464.	1.4	0
242	Assessment of BCR-ABL1 Transcript Levels By Digital PCR (dPCR) in CML Patients who Achieved a Deep Molecular Response (DMR: MR4.0, MR4.5 And MR5.0) with Tkis May Improve the Detection of Minimal Residual Disease (MRD) and the Selection of Patients for Treatment Free Remission (TFR). Blood, 2016, 128, 3096-3096.	1.4	0
243	Frontline Treatment with Dasatinib in Very Elderly Patients (> 75 Years) with Chronic Myeloid Leukemia: Is It Feasible?. Blood, 2018, 132, 5438-5438.	1.4	0
244	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Induces Genetic Instability and Can be Therapeutically Targeted. Blood, 2018, 132, 1726-1726.	1.4	0
245	Real Life Evaluation of Efficacy and Safety of Bosutinib Therapy in Chronic Myeloid Leukemia Patients. Blood, 2018, 132, 3021-3021.	1.4	0
246	Efficacy and Safety of Bosutinib in Chronic Phase CML Patients Developing Pleural Effusion Under Dasatinib Therapy. Blood, 2018, 132, 5439-5439.	1.4	0
247	First Interim Report of the Italian Multicentric Phase-III Randomized Study to Optimize TKIs Multiple Approaches - (OPTkIMA) in Elderly Patients (older than 60 years) with Ph+ Chronic Myeloid Leukemia (CML) and MR3.0/ MR4.0 Stable Molecular Response. Blood, 2018, 132, 4251-4251.	1.4	0
248	Risk Factors for Progression to Blast Phase and Outcome in 589 Patients with Myelofibrosis Treated with Ruxolitinib: Real-World Evidence. Blood, 2019, 134, 4166-4166.	1.4	0
249	Impact of Disease Burden in Myelofibrosis Patients: A Sub Analysis from Italian Romei Observational Study. Blood, 2019, 134, 4188-4188.	1.4	0
250	Aurora Kinase a/MDM2-Mediated SETD2 Loss of Function in Chronic Myeloid Leukemia Patients in Blast Crisis Can be Therapeutically Targeted Inducing Apoptotic Cell Death in a Caspase-Dependent Way. Blood, 2019, 134, 4142-4142.	1.4	0
251	Generic Versus Branded Imatinib As Frontline Therapy in Chronic-Phase Chronic Myeloid Leukemia Patients in Italy: A Case-Control Study. Blood, 2019, 134, 5909-5909.	1.4	0
252	Analysis of Early Events during the First Year of Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Phase - Chronic Myeloid Leukemia: A "Campus CML" Study. Blood, 2021, 138, 1487-1487.	1.4	0

#	Article	IF	Citations
253	Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study. Blood, 2020, 136, 47-48.	1.4	0
254	Low Cholesterol, Low-Density Lipoprotein (LDL) and Triglycerides Plasma Levels Are Associated with Lower Risk of Arterial Occlusive Events in Chronic Myeloid Leukemia Patients Treated with Nilotinib. Blood, 2020, 136, 8-9.	1.4	0
255	Ruxolitinib Rechallenge in Resistant/Intolerant MF Patients: Frequency, Therapeutic Effects, and Impact on Outcome. Blood, 2020, 136, 49-50.	1.4	0
256	First Line Treatment with Hydroxyurea in Patients with Policitemia Vera: Evaluation of Efficacy in the Current Clinical Practice Beyond ELN Criteria. Blood, 2020, 136, 43-44.	1.4	0